IPM Take
This is a patient-function story. Prostate cancer treatment often lasts long enough for side effects to become part of daily life, not just a line in a trial table. ARACOG matters because it asks whether two active treatments differ in how they affect cognition. That should matter to patients, families, clinicians and payers. Survival remains central, but if a man loses attention, memory or executive function during treatment, the system has to count that too.
Executive Summary
The Phase II ARACOG, AFT-47, trial compared darolutamide with enzalutamide in men with advanced prostate cancer. Presented at ASCO 2026, the study met its primary endpoint: median cognitive change from baseline to 24 weeks in the maximally changed cognitive domain was -15.8% with darolutamide versus -36.1% with enzalutamide. ASCO’s press programme framed the finding as less cognitive decline with darolutamide, while the ASCO abstract concluded that enzalutamide showed significantly greater decline across the individual cognitive domains tested.
Why it matters
- Clinicians: Cognitive function should be part of shared decision-making when choosing androgen receptor pathway inhibitors.
- HTA bodies / payers: Patient-centred endpoints can help differentiate therapies beyond standard survival and progression outcomes.
- Patients / advocates: Cognition, attention and independence are real treatment outcomes, especially for older patients and caregivers.
Prostate cancer treatment is often discussed through disease control: PSA response, metastasis risk, progression, survival. Those endpoints matter. But they do not capture everything that patients live with.
The ARACOG trial shifts attention to a quieter outcome: cognitive function. The study used objective cognitive testing across domains including executive function, working memory, visual memory and attention. The finding that darolutamide was associated with less decline than enzalutamide matters because cognitive change can affect work, driving, relationships, medication management and independence.
This does not mean cognition becomes the only factor in treatment choice. It means the access conversation becomes more honest. Two treatments may sit in the same therapeutic space, but they can still differ in the burden they place on a patient’s daily life.
For IPM, this is exactly where personalised oncology becomes more human. The right treatment is not only the one that controls disease. It is the one that fits the patient’s function, priorities and capacity to live well during therapy.
